Abstract

Pt(IV) complexes are known as prodrugs that can potentially overcome cisplatin limitations by slowing down its reactivity, and once reduced, act as the corresponding Pt(II) drugs. We report a new approach towards trans Pt(IV) complexes, conceived to afford nonconventional active trans Pt(II) complexes with dual targeting properties. The reduction of the complexes has been studied in the presence of ascorbic acid and glutathione, showing that different species are formed in the process. The interaction with DNA after reduction has been also studied and correlated to the formation of Pt(II) species. The cytotoxicity profile of the Pt(IV) complexes corroborated the rationale behind this approach.
Loading...

Quotes

0 citations in WOS
0 citations in

Journal Title

Journal ISSN

Volume Title

Publisher

American Chemical Society

Description

Este artículo describe la síntesis y caracterización de una familia de complejos de Pt(IV) con ligandos naftalimida como profármacos antitumorales y la evaluación de su actividad anticancerígena in vitro.

Citation

Francisco Navas, Filipa Mendes, Isabel Santos, Carmen Navarro-Ranninger, Silvia Cabrera, Adoración G. Quiroga. Inorganic Chemistry, 2017, 56, 6175-6183.

Endorsement

Review

Supplemented By

Referenced By

Statistics

Views
69
Downloads
34

Bibliographic managers

Document viewer

Select a file to preview:
Reload